News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Isis Pharmaceuticals, Inc. (ISIS) Expands Use of BioClinica, Inc.'s Express EDC


9/6/2012 10:16:20 AM

NEWTOWN, Pa.--(BUSINESS WIRE)--BioClinica®, Inc. (NASDAQ: BIOC), a leading global provider of clinical trial management solutions, announced today that Isis Pharmaceuticals will expand its current use of BioClinica’s Express Electronic Data Capture (EDC) solution to several upcoming trials. Isis is a global leader in antisense drug development with a broad pipeline of drugs that are applicable to many different disease targets. Isis's antisense technology provides a direct route from genes to drugs with the opportunity to dramatically improve industry drug discovery productivity.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES